- Home
- MFIN vs TARA Comparison
MFIN vs TARA Comparison
Compare MFIN & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MFIN | TARA |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.7M | 268.5M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | MFIN | TARA |
|---|---|---|
| Price | $9.40 | $5.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.00 | ★ $23.60 |
| AVG Volume (30 Days) | 44.9K | ★ 537.2K |
| Earning Date | 04-29-2026 | 05-01-2026 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.02 | N/A |
| P/E Ratio | $6.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.85 | $2.77 |
| 52 Week High | $11.00 | $7.82 |
Technical Indicators
Market Signals| Indicator | MFIN | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 58.82 | 42.56 |
| Support Level | $9.25 | $4.92 |
| Resistance Level | $10.35 | $5.44 |
| Average True Range (ATR) | 0.34 | 0.25 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 65.74 | 14.29 |
Price Performance
Historical ComparisonAbout MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).